You are here: Industry Insights > Eiger BioPharmaceuticals

News List

Eiger BioPharmaceuticals Announces First Patients Dosed with Peginterferon Lambda in Phase 3 TOGETHER Study of Newly Diagnosed COVID-19 Outpatients prnewswire
July 07, 2021
Eiger BioPharmaceuticals, Inc. today announced that the first patients were dosed with Peginterferon Lambda (Lambda) in the Phase 3 TOGETHER platform study in outpatients with COVID-19.
FDA Approves Zokinvy for Hutchinson-Gilford Progeria Syndrome americanpharmaceuticalreview
December 08, 2020
Eiger BioPharmaceuticals announced the U.S. Food and Drug Administration (FDA) has approved ZokinvyTM (lonafarnib) for the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and processing-deficient Progeroid Laminopathies (PL).
Eiger BioPharmaceuticals Announces Positive Results of Investigator Sponsored Randomized Controlled Trial at University of Toronto with Peginterferon Lambda in Outpatients with Mild to Moderate COVID- prnewswire
October 16, 2020
Eiger BioPharmaceuticals, Inc., focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, announced results of the ILIAD Study (Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in ...
Eiger Announces First COVID-19 Patients Dosed with Peginterferon Lambda americanpharmaceuticalreview
May 05, 2020
Eiger BioPharmaceuticals announced the first patients have been dosed in a Phase 2 study of peginterferon lambda (Lambda) in outpatients with mild COVID-19 at the Stanford University School of Medicine.
Eiger BioPharmaceuticals Completes Enrollment of Avexitide Study americanpharmaceuticalreview
August 14, 2018
Eiger BioPharmaceuticals announced completion of enrollment of the Phase 2 PREVENT study. PREVENT is a multi-center, placebo-controlled study investigating the safety......